According to Bloomberg in June, the White House has already concluded a similar deal, but the drug supply is slow.
According to his source, a deal between the Joe Biden administration and a pharmaceutical company that produces vaccines in cooperation with the German partner BioNTech may be concluded in the coming days. The agency’s source believes it will be announced on the eve of the COVID-19 summit, scheduled for September 22. The meeting, convened on Biden’s initiative, will be held in a virtual format on the sidelines of the UN General Assembly (GA).
It is expected that 500 million vaccine doses will be distributed among the countries in need through the international COVAX mechanism.
The agency notes that the White House had already concluded a similar deal with Pfizer in June, but the supply of the drug is slow. This, according to the agency, leads to the fact that “in many less affluent countries participating in COVAX, only a small part of the population has been vaccinated so far.”